Revenue
$2.18B
Fiscal year ended 2026-06-30Operating income
$326.10M
Fiscal year ended 2026-06-30Free cash flow
$393.60M
Fiscal year ended 2026-06-30ZIMMER BIOMET HOLDINGS, INC. (ZBH) reported revenue of $2.18B and net income of $198.30M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ZIMMER BIOMET HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.18B | $2.09B | $2.24B | $2.00B | $2.08B | $1.91B | $2.02B | $1.82B | $1.94B | $1.89B |
| Cost of revenue | $635.50M | $576.20M | $792.40M | $559.30M | $592.20M | $549.80M | $586.70M | $538.60M | $553.60M | $512.30M |
| Gross profit | $1.54B | $1.51B | $1.45B | $1.44B | $1.49B | $1.36B | $1.44B | $1.29B | $1.39B | $1.38B |
| Operating income | $326.10M | $373.20M | $154.50M | $351.30M | $300.00M | $292.30M | $389.00M | $279.50M | $351.30M | $265.90M |
| Net income | $198.30M | $238.10M | $139.30M | $230.90M | $152.80M | $182.00M | $239.50M | $249.10M | $242.80M | $172.40M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 192.80M | shares 195.80M | Unavailable | shares 198.80M | shares 198.30M | shares 199.70M | Unavailable | shares 203.00M | shares 206.40M | shares 206.20M |
| Pretax income | $255.10M | $301.30M | $98.00M | $279.20M | $224.60M | $229.00M | $289.00M | $230.30M | $302.20M | $215.10M |
| Income tax expense | $55.50M | $63.00M | -$39.90M | $48.00M | $71.20M | $46.50M | $48.90M | -$18.90M | $59.10M | $42.30M |
| Diluted EPS | $1.03 | $1.22 | Unavailable | $1.16 | $0.77 | $0.91 | Unavailable | $1.23 | $1.18 | $0.84 |
| Selling, general & administrative | $899.30M | $849.90M | $872.30M | $811.40M | $814.80M | $758.80M | $746.90M | $709.70M | $737.10M | $736.20M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | $1.38B | $525.50M | $569.00M | $420.10M | $393.00M |
| Total assets | $22.80B | $22.72B | $23.09B | $23.49B | $22.87B | $22.18B | $21.37B | $21.72B | $21.52B | $21.45B |
| Current assets | $5.10B | $4.96B | $5.12B | $5.83B | $5.05B | $5.59B | $4.67B | $4.86B | $4.64B | $4.63B |
| Total liabilities | $10.17B | $10.04B | $10.39B | $10.72B | $10.33B | $9.78B | $8.89B | $9.34B | $8.77B | $8.85B |
| Current liabilities | $3.01B | $2.86B | $2.58B | $2.40B | $2.70B | $2.29B | $2.45B | $3.57B | $3.61B | $2.80B |
| Total equity incl. NCI | $12.63B | $12.68B | $12.71B | $12.77B | $12.53B | $12.40B | $12.48B | $12.38B | $12.75B | $12.61B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $2.27B | $2.25B | $2.29B | $2.48B | $2.45B | $2.24B | $2.24B | $2.37B | $2.37B | $2.39B |
| Accounts receivable | $1.77B | $1.73B | $1.70B | $1.60B | $1.61B | $1.53B | $1.48B | $1.48B | $1.42B | $1.45B |
| Goodwill | $9.92B | $9.93B | $9.95B | $9.70B | $9.71B | $8.99B | $8.95B | $8.91B | $8.82B | $8.79B |
| Long-term debt | $6.28B | $6.30B | $6.93B | $7.51B | $6.75B | $6.58B | $5.34B | $4.74B | $3.96B | $4.83B |
| Accounts payable | $352.40M | $361.20M | $303.00M | $315.30M | $348.70M | $301.30M | $194.60M | $322.40M | $341.80M | $370.30M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $447.80M | $359.40M | $517.40M | $418.70M | $378.20M | $382.80M | $506.30M | $395.70M | $369.40M | $228.00M |
| Capital expenditures | $54.20M | $36.30M | $74.80M | $55.00M | $50.10M | $44.60M | $51.50M | $44.50M | $52.70M | $55.10M |
| Investing cash flow | -$190.80M | -$159.00M | -$322.00M | -$163.30M | -$1.38B | -$106.00M | -$291.20M | -$154.90M | -$247.00M | -$195.00M |
| Financing cash flow | -$271.10M | -$369.20M | -$897.00M | $483.80M | $163.80M | $575.40M | -$240.60M | -$101.90M | -$91.90M | -$50.10M |
| Net change in cash | -$14.20M | -$167.70M | -$700.80M | $735.80M | -$827.70M | $859.10M | -$43.60M | $148.90M | $27.10M | -$22.70M |
| Stock-based compensation | $24.60M | $24.20M | $24.10M | $25.30M | $21.20M | $19.60M | $21.10M | $24.50M | $26.40M | $29.00M |
| Common dividends paid | $46.50M | $46.90M | $47.50M | $47.50M | $47.50M | $47.80M | $48.00M | $49.20M | $49.40M | $49.40M |
| Common share repurchases | $250.70M | $250.10M | $250.00M | $0 | $7.20M | $229.80M | $72.20M | $596.30M | $85.90M | $113.60M |
| Depreciation & amortization | $270.80M | $270.00M | $284.00M | $283.60M | $271.80M | $254.40M | $263.60M | $250.90M | $243.30M | $238.60M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $393.60M | $323.10M | $442.60M | $363.70M | $328.10M | $338.20M | $454.80M | $351.20M | $316.70M | $172.90M |
| Gross margin | 70.8% | 72.4% | 64.7% | 72.1% | 71.5% | 71.2% | 71.0% | 70.5% | 71.5% | 72.9% |
| Operating margin | 15.0% | 17.9% | 6.9% | 17.6% | 14.4% | 15.3% | 19.2% | 15.3% | 18.1% | 14.1% |
| FCF margin | 18.1% | 15.5% | 19.7% | 18.2% | 15.8% | 17.7% | 22.5% | 19.3% | 16.3% | 9.2% |
| SBC / revenue | 1.1% | 1.2% | 1.1% | 1.3% | 1.0% | 1.0% | 1.0% | 1.3% | 1.4% | 1.5% |
| Current ratio | 1.69x | 1.73x | 1.98x | 2.43x | 1.87x | 2.44x | 1.91x | 1.36x | 1.29x | 1.66x |
| Revenue YoY growth | 4.8% | 9.3% | 10.9% | 9.7% | 7.0% | 1.1% | 4.3% | 4.0% | 3.9% | 3.2% |
| Net margin | 9.1% | 11.4% | 6.2% | 11.5% | 7.4% | 9.5% | 11.8% | 13.7% | 12.5% | 9.1% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 2.5% | 1.7% | 3.3% | 2.7% | 2.4% | 2.3% | 2.5% | 2.4% | 2.7% | 2.9% |
| Long-term debt / equity | 0.50x | Unavailable | 0.55x | 0.59x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 21.8% | 20.9% | -40.7% | 17.2% | 31.7% | 20.3% | 16.9% | -8.2% | 19.6% | 19.7% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZBH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-02-20View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-05View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.